News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Fredrik Wärnberg

Articles by Fredrik Wärnberg

38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram

ByJulie A. Margenthaler, MD,Karuna Mittal,Frank A. Vicini, MD,Chirag Shah, MD,Rachel Rabinovitch, MD,Pat W. Whitworth,Brian Czerniecki,David J. Dabbs,G. Bruce Mann,Fredrik Wärnberg,Sheila Weinmann,Michael Leo,Steven C. Shivers,Troy Bremer

April 26th 2023

39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

ByRachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Julie A. Margenthaler, MD,Brian Czerniecki,Pat W. Whitworth,David J. Dabbs,G. Bruce Mann,Fredrik Wärnberg,Sheila Weinmann,Michael Leo,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 26th 2023

40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

ByFrank A. Vicini, MD,Chirag Shah, MD,Rachel Rabinovitch, MD,Pat W. Whitworth,Julie A. Margenthaler, MD,Brian Czerniecki,David J. Dabbs,Sheila Weinmann,Michael Leo,G. Bruce Mann,Fredrik Wärnberg,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 26th 2023

37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

BySteven C. Shivers,Pat W. Whitworth,Rachel Rabinovitch, MD,Frank Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Karuna Mittal,Troy Bremer

May 6th 2022

38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

ByPat W. Whitworth,Rachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Steven C. Shivers,Karuna Mittal,Troy Bremer

May 6th 2022

Latest Updated Articles

Trending on CancerNetwork

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type

EDIC Displays Continuous Evolution as Variable in EOT Grade 3 Lymphopenia

How Can Oncology Staffing Shortages Be Remedied?

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

© 2025 MJH Life Sciences^®

All rights reserved.